# Monopar Therapeutics surges 41% premarket after showing tumor reduction benefit of its Camsirubicin from ongoing Phase 1b
**FDA Update**

**2023-11-01 11:41**

**https://www.ainvest.com/news/monopar-therapeutics-surges-41-premarket-after-showing-tumor-reduction-benefit-of-its-camsirubicin-from-ongoing-phase-1b-23111000d0c27b3c1be33924/**

Monopar Therapeutics surges 41% premarket after showing tumor reduction benefit of its Camsirubicin from ongoing Phase 1b